Endothelin-1 accentuates the proatherosclerotic effects associated with C-reactive protein.

[1]  A. Goldfine,et al.  Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. , 2006, Diabetes.

[2]  W. Sessa,et al.  PKC&agr; Activates eNOS and Increases Arterial Blood Flow In Vivo , 2005 .

[3]  L. Wold,et al.  Endothelin‐1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin‐1 , 2005, British journal of pharmacology.

[4]  S. Wedgwood,et al.  Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[5]  Jin Han,et al.  Endothelin-1 Acts via Protein Kinase C to Block KATP Channels in Rabbit Coronary and Pulmonary Arterial Smooth Muscle Cells , 2005, Journal of cardiovascular pharmacology.

[6]  S. Verma,et al.  Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation. , 2005, The Journal of thoracic and cardiovascular surgery.

[7]  T. Sawamura,et al.  C-Reactive Protein Enhances LOX-1 Expression in Human Aortic Endothelial Cells: Relevance of LOX-1 to C-Reactive Protein–Induced Endothelial Dysfunction , 2004, Circulation research.

[8]  G. Valen,et al.  Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion. , 2004, American journal of physiology. Heart and circulatory physiology.

[9]  R. Khalil,et al.  Endothelin-1 Promotes Ca2+ Antagonist-Insensitive Coronary Smooth Muscle Contraction Via Activation of &egr;-Protein Kinase C , 2004, Hypertension.

[10]  P. Libby,et al.  Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. , 2004, The American journal of medicine.

[11]  N. Hayashi,et al.  Regulation of endothelial nitric oxide synthase by protein kinase C. , 2003, Journal of biochemistry.

[12]  P. Ridker,et al.  C-reactive protein and other inflammatory risk markers in acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[13]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[14]  Philippe Robin,et al.  ET-1 stimulates ERK signaling pathway through sequential activation of PKC and Src in rat myometrial cells. , 2002, American journal of physiology. Cell physiology.

[15]  Paul M. Ridker,et al.  Prospective Study of C-Reactive Protein, Homocysteine, and Plasma Lipid Levels as Predictors of Sudden Cardiac Death , 2002, Circulation.

[16]  S. Verma,et al.  Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein , 2002, Circulation.

[17]  J. Manson,et al.  Is C-Reactive Protein Specific for Vascular Disease in Women? , 2002, Annals of Internal Medicine.

[18]  P. Ridker,et al.  Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. , 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.

[19]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[20]  N Rifai,et al.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.

[21]  N Rifai,et al.  High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. , 2001, Clinical chemistry.

[22]  G. Rieder,et al.  Endothelin in coronary endothelial dysfunction early after human heart transplantation. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[24]  T. Lüscher,et al.  Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Xiaopeng Zhou,et al.  Endothelin-1-induced mesangial cell contraction involves activation of protein kinase C-α, -δ, and -ε. , 1998, American journal of physiology. Renal physiology.

[26]  A. Gallino,et al.  Endothelial dysfunction and accelerated coronary artery disease in cardiac transplant recipients , 1997 .

[27]  R. Weisel,et al.  Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C. , 1997, The American journal of physiology.

[28]  J. Vachiéry,et al.  Plasma endothelin and early coronary endothelial dysfunction in recipients of a cardiac transplant. , 1995, American heart journal.

[29]  M. Polokoff,et al.  Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. , 1994, Pharmacological reviews.

[30]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[31]  T. Lüscher.  Endothelin. Key to coronary vasospasm? , 1991, Circulation.

[32]  G. King,et al.  Characterization of Endothelin Receptors and Effects of Endothelin on Diacylglycerol and Protein Kinase C in Retinal Capillary Pericytes , 1989, Diabetes.

[33]  G. King,et al.  Endothelin stimulates a sustained 1,2-diacylglycerol increase and protein kinase C activation in bovine aortic smooth muscle cells. , 1989, Biochemical and biophysical research communications.

[34]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[35]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[36]  W. Sessa,et al.  PKCalpha activates eNOS and increases arterial blood flow in vivo. , 2005, Circulation research.

[37]  P. Ridker,et al.  C-reactive protein, inflammation, and coronary risk. , 2000, The Medical clinics of North America.

[38]  A. Gallino,et al.  Endothelial dysfunction and accelerated coronary artery disease in cardiac transplant recipients. Microcirculation Working Group, European Society of Cardiology. , 1997, European heart journal.